Sofiva Genomics (6615) reported revenue of NT$30.2 million for Oct 2026, -3.0% year on year and -1.2% from the previous month. Revenue for Jan–Oct 2026 was NT$314.9 million (-1.9% year on year).
In Oct 2026, it ranked No. 118 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$30.2 million | -3.0% | -1.2% |
| Sep 2026 | NT$30.5 million | +1.8% | +0.6% |
| Aug 2026 | NT$30.4 million | -2.4% | -9.8% |
| Jul 2026 | NT$33.7 million | +4.3% | +4.1% |
| Jun 2026 | NT$32.3 million | -2.5% | -4.2% |
| May 2026 | NT$33.7 million | -1.7% | +11.9% |
| Apr 2026 | NT$30.2 million | -9.1% | -12.2% |
| Mar 2026 | NT$34.4 million | +2.8% | +30.0% |
| Feb 2026 | NT$26.4 million | -15.7% | -20.1% |
| Jan 2026 | NT$33.1 million | +6.3% | -1.9% |
| Dec 2025 | NT$33.7 million | -3.4% | +9.3% |
| Nov 2025 | NT$30.9 million | -4.9% | -0.8% |
| Oct 2025 | NT$31.1 million | -13.9% | +3.7% |
| Sep 2025 | NT$30 million | -11.3% | -3.6% |
| Aug 2025 | NT$31.1 million | -17.8% | -3.5% |
| Jul 2025 | NT$32.3 million | -6.6% | -2.7% |
| Jun 2025 | NT$33.2 million | -19.7% | -3.4% |
| May 2025 | NT$34.3 million | -13.6% | +3.5% |
| Apr 2025 | NT$33.2 million | -20.0% | -0.8% |
| Mar 2025 | NT$33.4 million | -22.3% | +6.6% |
| Feb 2025 | NT$31.4 million | -12.5% | +0.8% |
| Jan 2025 | NT$31.1 million | -26.2% | -10.9% |
| Dec 2024 | NT$34.9 million | -13.6% | +7.6% |
| Nov 2024 | NT$32.4 million | -9.2% | -10.1% |
| Oct 2024 | NT$36.1 million | -6.7% | +6.8% |
Jan–Oct 2026 cumulative: NT$314.9 million (-1.9% YoY)
Other Biotech & Medical companies
Compare with peers: Sofiva Genomics vs PEC / Sofiva Genomics vs Lotus Pharm / Sofiva Genomics vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16